HOME >> BIOLOGY >> NEWS
Acamprosate: potential medication for treating alcoholism

laces and things associated with alcohol) and reduce alcohol consumption, leading to less relapse drinking and more abstinent days. Although it is well tolerated and does not produce many adverse effects, naltrexone does not work for everyone, leading some scientists to think there are genetic differences behind the treatment response.

For this study, adult participants (7 males, 3 females) were recruited through local advertising. All of the participants were classified as heavy drinkers, having reported alcohol consumption a minimum of eight days per month; with five or more drinks per occasion at least three times a month for the men, and four or more drinks per occasion at least three times a month for the women. During the six-week study, subjects received three different doses of oral acamprosate (0, 2 and 4 g.) for 11 days on each dose. Physiological, subjective and psychomotor measures were collected daily during each dosing cycle. During each of the acamprosate dose conditions, subjects also received three different doses of alcohol (0, 0.5 and 1.0 g/kg) during three separate laboratory sessions. Researchers collected the subjective, physiological and psychomotor effects of the alcohol as well as breath-alcohol levels at baseline and at 30-minute intervals for three hours following administration.

Results indicate that acamprosate does not appear to alter alcohol's pharmacokinetics (the way it moves through the body), acute physiological or psychomotor alcohol effects, or most subjective alcohol effects.

"While the results of this study are rather clear and straightforward, namely, that acamprosate has minimal effects on the alcohol experience, the findings should be interpreted cautiously because only a few subjects were studied and those subjects were not alcoholics," said Anton. "Since people vary in medication response, generalizing from a study of only a few people is difficult. Also, we know tha
'"/>


14-Jul-2004


Page: 1 2 3 4

Related biology news :

1. Award winning researchers reveal potential new role for Glivec
2. Evidence builds for potential new cancer drug target
3. Scientists discover potential new way to control drug-resistant bacteria
4. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
5. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
6. Managing occupational exposures to potential bioterrorist agents
7. Location of potential familial lung cancer gene discovered
8. Common chemicals morphing into potential toxins in Arctic
9. Yale researchers discover new potential asthma therapeutic targets related to parasites and insects
10. Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
11. New screening method turns up potential compound for treating anthrax

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acamprosate potential medication for treating alcoholism

(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is ... been elected Chairman of the Board, to succeed Donald ... CEO, but will continue as a member of the Board.  ... has added to the company over almost twenty years, the ... The Board of Directors has established a Search Committee to ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
Cached News: